New arthritis drug shows promise in early safety trial
NCT ID NCT03574545
First seen Jan 05, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This study looked at two versions of an experimental drug called ianalumab (VAY736) in 48 adults with rheumatoid arthritis. The goal was to check if the two versions are similar in how they work in the body and to see if they are safe. Participants received multiple doses of the drug under the skin. The study was completed and focused on safety and drug levels, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.